Biovigilance and pharmacovigilance for haemophilia

Haemophilia

Volumn 16, Issue SUPPL. 5, 2010, Pages 17-21

  Weinstein, M ^a   Makris, M ^b   Ludlam, C A ^c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Adverse events; Biovigilance; Haemophilia; Pharmacovigilance

Indexed keywords

BLOOD DERIVATIVE;

BLOOD TRANSFUSION; DISEASE SURVEILLANCE; DRUG SURVEILLANCE PROGRAM; GOOD MANUFACTURING PRACTICE; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH PROGRAM; HEMOPHILIA; HEPATITIS A; HUMAN; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BLOOD COAGULATION FACTORS; EUROPE; HEMOPHILIA A; HUMANS; NORTH AMERICA; PRODUCT SURVEILLANCE, POSTMARKETING; RISK MANAGEMENT; WORLD HEALTH;

EID: 77955036315     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02288.x     Document Type: Review

References (7)

1. Biovigilance In The United States: Efforts To Bridge A Critical Gap In Patient Safety And Donor Health. http://www.hhs.gov/ophs/bloodsafety/biovigilance/index.html, Ash_acbsa_oct_2009.pdf
2. Notice to Readers Bacterial Sepsis Associated with Receipt of Albumin. MMWR Weekly. Notice to Readers Bacterial Sepsis Associated with Receipt of Albumin October 11, 1996, 45:866-7.
3. Dilution, counterfeiting of biotechnology products discovered. Biotechnology Law Report. 2002, 21:366-366.
4. Haniff H. Heparin products the targets of deliberate adulteration, says Baxter CEO. Biopharminternational.com, May 8, 2008
5. Hepatitis A Among persons with haemophilia who received clotting factor concentrate - United States. September-December 1996. MMWR Weekly 1996, 45:29-32.
6. Kurnik K, Thomas AE. Meeting report: ninth and tenth workshops of the European Paediatric Network for Haemophilia Management (PedNet). Haemophilia 2007, 13:658-62.
7. Chalmers EA, Brown SA, Keeling D. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007, 13:149-55.